Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
CD134 / OX40 agonists have shown promise in preclinical models by enhancing anti-tumor immunity and improving tumor-free survival. They activate T cells within tumors, bolstering the immune response against various cancers, including sarcoma, breast cancer, and glioma. These agonists can modulate the tumor microenvironment by increasing effector T cells and reducing regulatory T cells (Tregs), which suppress immune responses
see also:
[CD134 / OX40 agonists](brain://cPFMZQ74KE-vIRU5dYfgaw/Cd13…